KX826 New Phase 3 Trial In China for 2025: 1.0% concentration
    Research/Science 1/10/2025

    At a glance
    In this research discussion post, the primary subjects mentioned are
    💧 KX-826 (topical) 1.0%
    the tone is 😐 neutral with varied opinions results.
    KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.
    View this post in the Community →

    Similar Community Posts Join

    6 / 215 results

    Related Research

    6 / 129 results